Tenofovir Gel in Pregnancy and Lactation
Completed · Phase 1 · Has a placebo group
Conditions studied: HIV Infections
In brief
Tenofovir 1% gel is an investigational vaginal microbicide intended to reduce the risk of transmission of HIV. Pregnant women and mothers who have recently given birth often maintain sexual activity, and research has shown that they may be at greater risk of HIV infection during pregnancy. Microbicides may be able to prevent HIV infection during pregnancy, which would also prevent fetal exposure to HIV. This study will test the safety of using tenofovir 1% gel in healthy, pregnant women and healthy, breastfeeding women.
Key facts
- Study ID
- NCT01136759
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 232
- Starts
- 2011-03-01
- Expected to finish
- 2013-09-01
- Last updated by the study team
- 2021-10-25
Who can join
Age: 18 and older, up to 40. Sex: female. Healthy volunteers: accepted.
Where it is running
- Alabama CRS — Birmingham, Alabama, United States
- University of Pittsburgh CRS — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.